Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1953 1
1956 1
1968 1
1970 2
1971 1
1972 3
1973 1
1974 1
1975 1
1976 1
1977 2
1979 2
1980 3
1981 3
1982 6
1983 3
1984 2
1985 1
1986 8
1987 5
1988 20
1989 10
1990 12
1991 7
1992 5
1993 16
1994 13
1995 11
1996 15
1997 13
1998 11
1999 15
2000 4
2001 5
2002 8
2003 6
2004 2
2005 11
2006 6
2007 2
2008 4
2009 5
2010 8
2011 6
2013 2
2014 3
2015 6
2016 6
2017 5
2018 6
2019 5
2020 5
2021 7
2022 9
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

310 results

Results by year

Filters applied: . Clear all
Page 1
Interleukin-10 and the interleukin-10 receptor.
Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Moore KW, et al. Among authors: coffman rl. Annu Rev Immunol. 2001;19:683-765. doi: 10.1146/annurev.immunol.19.1.683. Annu Rev Immunol. 2001. PMID: 11244051 Review.
Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.
Bateman RJ, Smith J, Donohue MC, Delmar P, Abbas R, Salloway S, Wojtowicz J, Blennow K, Bittner T, Black SE, Klein G, Boada M, Grimmer T, Tamaoka A, Perry RJ, Turner RS, Watson D, Woodward M, Thanasopoulou A, Lane C, Baudler M, Fox NC, Cummings JL, Fontoura P, Doody RS; GRADUATE I and II Investigators and the Gantenerumab Study Group. Bateman RJ, et al. N Engl J Med. 2023 Nov 16;389(20):1862-1876. doi: 10.1056/NEJMoa2304430. N Engl J Med. 2023. PMID: 37966285 Clinical Trial.
Adjuvanting a subunit COVID-19 vaccine to induce protective immunity.
Arunachalam PS, Walls AC, Golden N, Atyeo C, Fischinger S, Li C, Aye P, Navarro MJ, Lai L, Edara VV, Röltgen K, Rogers K, Shirreff L, Ferrell DE, Wrenn S, Pettie D, Kraft JC, Miranda MC, Kepl E, Sydeman C, Brunette N, Murphy M, Fiala B, Carter L, White AG, Trisal M, Hsieh CL, Russell-Lodrigue K, Monjure C, Dufour J, Spencer S, Doyle-Meyers L, Bohm RP, Maness NJ, Roy C, Plante JA, Plante KS, Zhu A, Gorman MJ, Shin S, Shen X, Fontenot J, Gupta S, O'Hagan DT, Van Der Most R, Rappuoli R, Coffman RL, Novack D, McLellan JS, Subramaniam S, Montefiori D, Boyd SD, Flynn JL, Alter G, Villinger F, Kleanthous H, Rappaport J, Suthar MS, King NP, Veesler D, Pulendran B. Arunachalam PS, et al. Among authors: coffman rl. Nature. 2021 Jun;594(7862):253-258. doi: 10.1038/s41586-021-03530-2. Epub 2021 Apr 19. Nature. 2021. PMID: 33873199
Assessing the safety of adjuvanted vaccines.
Ahmed SS, Plotkin SA, Black S, Coffman RL. Ahmed SS, et al. Among authors: coffman rl. Sci Transl Med. 2011 Jul 27;3(93):93rv2. doi: 10.1126/scitranslmed.3002302. Sci Transl Med. 2011. PMID: 21795590 Review.
A review of TNP-ATP in protein binding studies: benefits and pitfalls.
Woodbury DJ, Whitt EC, Coffman RE. Woodbury DJ, et al. Among authors: coffman re. Biophys Rep (N Y). 2021 Aug 6;1(1):100012. doi: 10.1016/j.bpr.2021.100012. eCollection 2021 Sep 8. Biophys Rep (N Y). 2021. PMID: 36425312 Free PMC article. Review.
Vaccine adjuvants: putting innate immunity to work.
Coffman RL, Sher A, Seder RA. Coffman RL, et al. Immunity. 2010 Oct 29;33(4):492-503. doi: 10.1016/j.immuni.2010.10.002. Immunity. 2010. PMID: 21029960 Free PMC article. Review.
The stability and reversibility of Th1 and Th2 populations.
Coffman RL, Mocci S, O'Garra A. Coffman RL, et al. Curr Top Microbiol Immunol. 1999;238:1-12. doi: 10.1007/978-3-662-09709-0_1. Curr Top Microbiol Immunol. 1999. PMID: 10087647 Review. No abstract available.
310 results